These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 15963867

  • 1. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB, Roberts MS, Woodson ME, Shi M, Swanton RE, Reder RF, Buckley BJ.
    J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
    [Abstract] [Full Text] [Related]

  • 2. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA.
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
    Vashi V, Harris S, El-Tahtawy A, Wu D, Cipriano A.
    J Clin Pharmacol; 2005 May; 45(5):547-54. PubMed ID: 15831778
    [Abstract] [Full Text] [Related]

  • 4. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
    Hagen NA, Babul N.
    Cancer; 1997 Apr 01; 79(7):1428-37. PubMed ID: 9083166
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
    Ridgway D, Sopata M, Burneckis A, Jespersen L, Andersen C.
    J Pain Symptom Manage; 2010 Apr 01; 39(4):712-20. PubMed ID: 20413058
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK, Bijur PE, Baccelieri A, Gallagher EJ.
    Am J Geriatr Pharmacother; 2009 Feb 01; 7(1):1-10. PubMed ID: 19281935
    [Abstract] [Full Text] [Related]

  • 7. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
    Junker U, Figge V.
    MMW Fortschr Med; 2005 Oct 06; 147 Suppl 3():91-6. PubMed ID: 16261943
    [Abstract] [Full Text] [Related]

  • 8. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R.
    Pain Pract; 2010 Oct 06; 10(5):404-15. PubMed ID: 20384968
    [Abstract] [Full Text] [Related]

  • 9. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
    Hale M, Khan A, Kutch M, Li S.
    Curr Med Res Opin; 2010 Jun 06; 26(6):1505-18. PubMed ID: 20429852
    [Abstract] [Full Text] [Related]

  • 10. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr 06; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 11. Randomized clinical trial comparing a patient-driven titration protocol of intravenous hydromorphone with traditional physician-driven management of emergency department patients with acute severe pain.
    Chang AK, Bijur PE, Davitt M, Gallagher EJ.
    Ann Emerg Med; 2009 Oct 06; 54(4):561-567.e2. PubMed ID: 19560838
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H, Kerwin R.
    Clin Ther; 2007 Jun 06; 29(6):1000-12. PubMed ID: 17692717
    [Abstract] [Full Text] [Related]

  • 13. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH, Gould E.
    Clin Ther; 2009 Feb 06; 31(2):347-59. PubMed ID: 19302907
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM.
    J Pain; 2014 Aug 06; 15(8):835-44. PubMed ID: 24846822
    [Abstract] [Full Text] [Related]

  • 15. Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
    Cruciani RA, Katz N, Portenoy RK.
    J Pain; 2012 Apr 06; 13(4):379-89. PubMed ID: 22424912
    [Abstract] [Full Text] [Related]

  • 16. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct 06; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
    Currow DC, Plummer JL, Cooney NJ, Gorman D, Glare PA.
    J Pain Symptom Manage; 2007 Jul 06; 34(1):17-23. PubMed ID: 17601560
    [Abstract] [Full Text] [Related]

  • 18. Oral hydromorphone extended-release.
    Guay DR.
    Consult Pharm; 2010 Dec 06; 25(12):816-28. PubMed ID: 21172762
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
    Shram MJ, Sathyan G, Khanna S, Tudor IC, Nath R, Thipphawong J, Sellers EM.
    J Clin Psychopharmacol; 2010 Feb 06; 30(1):25-33. PubMed ID: 20075644
    [Abstract] [Full Text] [Related]

  • 20. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A, Ma C, Ahdieh H, Galer BS.
    Clin Ther; 2006 Mar 06; 28(3):352-64. PubMed ID: 16750450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.